Safe and effective stroke prevention in atrial fibrillation (AF) is crucial as the number of patients with this condition continues to increase. Several novel oral anticoagulants are being developed ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

The US Food and Drug Administration (FDA) has approved Andexxa (coagulation factor Xa [recombinant] inactivated-zhzo) to reverse the anticoagulation effects of factor Xa inhibitors when needed due to ...

SAN FRANCISCO, CA – A phase 3 study designed to test an antidote to the factor Xa inhibitor class of novel anticoagulants met its primary efficacy end point, according to an announcement from Portola ...

Among patients hospitalized with life-threatening or uncontrolled bleeding related to direct factor Xa inhibition, in-hospital and 30-day mortality vary based the type of reversal agent used, with ...

Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers. In this multicenter, prospective, ...

Please provide your email address to receive an email when new articles are posted on . In recent years, medicine has witnessed the arrival of the direct oral anticoagulants, which include the direct ...

Please provide your email address to receive an email when new articles are posted on . In patients with nonvalvular atrial fibrillation receiving oral anticoagulants, factor Xa inhibitors appeared ...

Andexanet alfa (andexanet) rapidly reverses anti-factor Xa activity in patients with acute major bleeding associated with factor Xa inhibitor therapy. This finding comes from the ANNEXA-4 trial, which ...

New research sheds light on the mechanism by which Rivaroxaban suppresses factor Xa and successfully attenuates atherosclerosis. New research by a team led by researchers from the Department of ...